Navigation Links
Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
Date:4/29/2008

Demonstration Signifies Completion of First Disease Database for the

VentriPoint Diagnostic System

SEATTLE, April 29 /PRNewswire/ -- VentriPoint Diagnostics today announced that Knowledge Based Reconstruction (KBR) enables accurate three dimensional reconstruction of right ventricular volume and function in patients with tetralogy of fallot (TOF) in significantly less time and for a lower cost than currently applied methods.

TOF is a disease that impacts the heart in multiple ways, such as creating a hole between the ventricles and developing levels of obstruction from the right ventricle to the lungs known as pulmonary stenosis. The three dimensional models also provided an understanding of changes to the shape of the right ventricle that doctors can use to analyze how the heart adapts to hemodynamic overload.

In a study of 20 patients with repaired TOF led by Florence H. Sheehan, M.D., of the University of Washington, the accuracy of the volume and ejection fraction of the right ventricle obtained with KBR was equal to or greater than the published accuracy of other methods of measurement. Using the VentriPoint Diagnostic System, KBR was applied as anatomical points identified on two dimensional images of the right ventricle of TOF diseased hearts were referenced with the KBR database comprised of 110 patients, including 54 with TOF. This is the first of four unique disease-specific KBR databases that VentriPoint is developing and plans to deploy when the VentriPoint Diagnostic System becomes commercially available.

"Applying Knowledge Based Reconstruction, our VentriPoint Diagnostic System completes critical ventricular measurements in significantly less time and lower cost than traditional methods to enable the cardiologists to better diagnose, monitor and track the efficacy of treatments," said Joseph Ashley, CEO of VentriPoint Diagnostics. "This validation of the tetralogy of fallot Knowledge Based Reconstruction database confirms the effectiveness of our collaborations and processes as we expand and accelerate the development of additional databases specific to other forms of congenital heart disease and proceed with our plans to initiate sales of the VentriPoint Diagnostic System in early 2009."

The VentriPoint Diagnostic System uses imaging systems currently employed in most hospitals and accesses the KBR database via the Internet. Using the device and the KBR technique, a three dimensional model of the ventricle and its measurements can be completed in only a few minutes longer than a traditional echocardiogram.

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates critical heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon technology received by VentriPoint through its technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

VentriPoint Media Contacts:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.


'/>"/>
SOURCE VentriPoint Diagnostics Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
2. ActiveSight and CHDI Leverage Fragment-Based Lead Discovery for Huntington Disease Therapies
3. Vical Demonstrates Dose-sparing of Protein-based H5N1 Influenza Vaccine With Vaxfectin(TM) Adjuvant
4. Groundbreaking Study Proves Personalized Diet Based on Genetics Leads to Significant Advances in Long Term Weight Management and Blood Glucose Levels
5. Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
6. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
7. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
8. New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
9. Boehringer Ingelheim Initiates NEwArT Study Comparing Viramune(R) (nevirapine) to a Ritonavir-Boosted Atazanavir-based Regimen in Treatment-Naive HIV Patients
10. ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
11. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)...   The Accreditation Council for Medical Affairs ... the pharmaceutical industry has appointed Dr. Jane ... formed scientific advisory board. Dr. Chin will be ... ever medical affairs think tank within the pharmaceutical ... ACMA, please visit  www.medicalaffairsspecialist.org .  Connect with ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
(Date:3/24/2017)... March 24, 2017 Today Stock-Callers.com have ... which are: Neovasc Inc. (NASDAQ: NVCN), Hologic Inc. (NASDAQ: HOLX), ... SSH ). These companies are part of the ... on Thursday, March 23 rd , 2017, with the NYSE ... of health care companies in the S&P 500 were down ...
Breaking Medicine Technology:
(Date:3/24/2017)... NY (PRWEB) , ... March 24, 2017 , ... ... scale; from third world countries to hospitals in the United States, it’s a ... conversation on the current obstacles facing infection prevention and offers strategies for the ...
(Date:3/24/2017)... ... March 24, 2017 , ... According to a new study by NCPA ... does not obey the rules Congress has directed the CBO to follow. The CBO ... reform would restore. Yet, it estimates a reduction in employer-based coverage due to the ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... planning, and related services to families and business owners across eastern Michigan, is ... feeding regional families struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry ...
(Date:3/24/2017)... , ... March 24, 2017 , ... ... Society (ONS) wanted to create a communications platform that positions them as the ... Elliance and ONS reinvented their online publication as an always-on, always-fresh news, views ...
(Date:3/24/2017)... Westchester County, NY (PRWEB) , ... March 24, 2017 , ... ... in Somers and White Plains, N.Y., is pleased to announce Westchester resident Lauren C. ... as a law clerk for the firm, will concentrate her practice in elder law, ...
Breaking Medicine News(10 mins):